Acurx Pharmaceuticals
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
259 Liberty Ave, Staten Island, New York...Phone Number
(917) 533-1469Website
www.acurxpharma.comRevenue
-Stock Symbol
ACXPIndustry
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. is a New York-based publicly held clinical-stage biopharmaceutical company developing antibiotics for infections caused by priority bacterial pathogens. Its research focuses on DNA polymerase IIIC inhibition, with lead candidate ibezapolstat in clinical trials for C. difficile infections and additional early-stage antibiotic programs targeting difficult-to-treat Gram-positive infections. The company trades on the public market under the ticker ACXP.Explore more
Acurx Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Acurx Pharmaceuticals
Compare insights from companies similar to Acurx Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Acurx Pharmaceuticals Tech Stack
A closer look at the technologies used by Acurx Pharmaceuticals
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acurx Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Acurx Pharmaceuticals, Inc. is a New York-based publicly held clinical-stage biopharmaceutical company developing antibiotics for infections caused by priority bacterial pathogens. Its research focuses on DNA polymerase IIIC inhibition, with lead candidate ibezapolstat in clinical trials for C. difficile infections and additional early-stage antibi... Read More
